Dr Reddys Laboratories has reported results for its first quarter ended June 30, 2011.
The company’s net profit for the quarter has surged by 25.38% at Rs 262.74 crore as compared to Rs 209.55 crore for the quarter ended June 30, 2010. Its net income from sales and services has increased by 17.54% to Rs 1978.32 crore for the quarter under review from Rs 1683.13 crore for the corresponding quarter of the previous year.
Dr Reddys, a global pharmaceutical company, has a global presence in more than 100 countries, with subsidiaries in the US, UK, Russia, Germany and Brazil; joint ventures in China, South Africa and Australia; representative offices in 16 countries and third-party distribution set ups in 21 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.70 |
| Dr. Reddys Lab | 1219.10 |
| Cipla | 1237.50 |
| Zydus Lifesciences | 931.60 |
| Lupin | 2303.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: